Cover Image

Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China

ObjectiveThis study aimed to investigate the association between the utilization of Sodium-dependent glucose cotransporters inhibitors (SGLT2i) in real-world settings and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in mainland China.MethodsIn a retrospecti...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiang Xiao (Author), Shuming Ji (Author), Tao Zheng (Author), Tianzhu Wang (Author), Dapeng Jiang (Author), Fang Liu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
by: Feng Liu, et al.
Published: (2023)

Intravitreal vascular endothelial growth factor inhibitors did not increase the risk of end-stage renal disease in patients with biopsy-proven diabetic kidney disease based on matched study
by: Xiang Xiao, et al.
Published: (2022)

Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world
by: Rongjing Song, et al.
Published: (2024)

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
by: Yu-jie Xing, et al.
Published: (2021)

SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
by: Jasna Klen, et al.
Published: (2023)

A cell-based fluorescent glucose transporter assay for SGLT2 inhibitor discovery
by: Yi Huan, et al.
Published: (2013)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
by: Xiang Zhou, et al.
Published: (2021)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
by: Lingxiang Xie, et al.
Published: (2022)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
by: Zhen Feng, et al.
Published: (2022)

Industrial-Scale Preparation of a Key Intermediate for the Manufacture of Therapeutic SGLT2 Inhibitors
by: Lei Huang, et al.
Published: (2022)

Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
by: Rabab Mahmoud Ahmed, et al.
Published: (2024)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023)

Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study
by: Mar Garcia Zamora, et al.
Published: (2024)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019)

Impact of SGLT2 inhibitors on lower limb complications: a mendelian randomization perspective
by: Baixing Chen, et al.
Published: (2024)

SGLT-2 Inhibitors in Kidney Transplant Recipients: Our Story So Far
by: Luís Leite de Sousa, et al.
Published: (2023)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019)

Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study
by: Antonio Rodríguez-Miguel, et al.
Published: (2024)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017)

Novel and Practical Industrial Process Scale-Up of 5-Bromo-2-chloro-4-(methoxycarbonyl)benzoic acid, a Key Intermediate in the Manufacturing of Therapeutic SGLT2 Inhibitors
by: Yi Zhang, et al.
Published: (2022)

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
by: Apichaya Chanawong, et al.
Published: (2023)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
by: Chun Xing Li, et al.
Published: (2023)

Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis
by: Fan Yang, et al.
Published: (2023)

The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study
by: Yi-Chang Zhao, et al.
Published: (2022)

Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study
by: Ni Zhang, et al.
Published: (2024)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
by: Eva M Vivian
Published: (2014)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019)

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
by: Marcin Czarkowski, et al.
Published: (2022)

The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study
by: Pasquale Pignatelli, et al.
Published: (2022)

Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
by: Xiuping Liang, et al.
Published: (2022)

Use systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
by: Yasong eLu, et al.
Published: (2014)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
by: Joshua J Neumiller
Published: (2014)

Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice
by: Hiroshi Yaginuma, et al.
Published: (2021)

Unlocking the potential: boosting SGLT2 inhibitor uptake to prevent the cardiorenal consequences of chronic kidney disease
by: Julio A. Lamprea-Montealegre
Published: (2024)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)